Thalidomide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Thalidomide |
| DrugBank ID | DB01041 |
| Brand Names (EU) | Thalidomide BMS (previously Thalidomide Celgene) |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.96% |
Approved Indication (EMA)
Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | ganglioneuroblastoma (disease) | 98.96% | DL |
| 2 | vertebral anomalies and variable endocrine and T-cell dysfunction | 98.95% | DL |
| 3 | retroperitoneal neoplasm | 98.68% | DL |
| 4 | neuroblastoma | 98.66% | DL |
| 5 | brachydactyly-syndactyly syndrome | 94.22% | DL |
| 6 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 93.20% | DL |
| 7 | rheumatoid arthritis | 92.40% | DL |
| 8 | myeloid leukemia | 90.54% | DL |
| 9 | indolent plasma cell myeloma | 88.46% | DL |
| 10 | plasma cell myeloma | 85.34% | DL |
| 11 | acute lymphoblastic leukemia (disease) | 74.75% | DL |
| 12 | cholangiocarcinoma, susceptibility to | 64.32% | DL |
| 13 | GCGR-related hyperglucagonemia | 60.49% | DL |
| 14 | scalp dermatosis | 59.90% | DL |
| 15 | congenital temporomandibular joint ankylosis | 59.59% | DL |
| 16 | polydipsia | 59.20% | DL |
| 17 | mitral valve prolapse, myxomatous | 58.87% | DL |
| 18 | epidural abscess | 57.97% | DL |
| 19 | giant cell reparative granuloma | 57.02% | DL |
| 20 | pancreas, dorsal, agenesis of | 56.94% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.